Table 1

Summary of the clinical effects of colesevelam in patients with type 2 diabetes

StudynDuration (weeks)Background therapyTreatmentBaseline HbA1c (%)Treatment difference: HbA1c (%)Treatment difference: LDL cholesterol (%)
Bays et al. (17)31626Metformin-based therapyColesevelam 3.75 g/day (n = 159); Placebo (n = 157)8.1−0.54−15.9
Fonseca et al. (18)46126Sulfonylurea-based therapyColesevelam 3.75 g/day (n = 230); Placebo (n = 231)8.2−0.54−16.7
Goldberg et al. (19)28716Insulin-based therapyColesevelam 3.75 g/day (n = 147); Placebo (n = 140)8.3−0.50−12.8
Goldfine et al. (25)50952Metformin-, sulfonylurea-, or insulin-based therapyColesevelam 3.75 g/day (n = 509)8.2−0.3*Not reported
Rigby et al. (42)16916Metformin monotherapyColesevelam 3.75 g/day (n = 57); Rosiglitazone 4 mg/day (n = 56); Sitagliptin 100 mg/day (n = 56)8.1−0.3*−11.6*
  • Treatment difference = colesevelam – placebo.

  • *Mean change from baseline.

  • P < 0.001 vs. placebo.

  • P ≤ 0.001 vs. baseline.

  • P < 0.05 vs. baseline.